Enterprise Value

-1.863B

Cash

2.285B

Avg Qtr Burn

N/A

Short % of Float

0.89%

Insider Ownership

1.06%

Institutional Own.

42.03%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Eftansomatropin alfa (TJ101) Details
Pediatric growth hormone deficiency

BLA

Submission

Lemzoparlimab combo w/ azacitidine Details
High risk myelodysplastic syndromes

Phase 3

Data readout

Phase 3

Data readout

Efineptakin alfa (TJ107) (IL-7) Details
Lymphopenia, Solid tumor/s, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma, Glioblastoma

Phase 2

Data readout

Phase 2

Data readout

Uliledlimab (TJD5) (TJ004309) (anti-CD73) Details
Cancer, Non-small cell lung carcinoma

Phase 2

Update

Felzartamab Details
Primary Membranous Nephropathy

Phase 1/2

Update

MOR210 (TJ210) Details
Solid tumor/s, Cancer

Phase 1

Data readout

Phase 1

Data readout

Phase 1

Data readout

Failed

Discontinued

Olamkicept (TJ301) (gp130 IL-6 inhibitor) Details
Ulcerative colitis, Autoimmune disease

Failed

Discontinued

Enoblituzumab (TJ271) + Pembrolizumab Details
Head and neck cancer, Cancer, Prostate cancer, Solid tumor/s

Failed

Discontinued